Finder is committed to editorial independence. While we receive compensation when you click links to partners, they do not influence our content.

How to buy Editas Medicine (EDIT) stocks in Canada

Learn how to easily invest in Editas Medicine stocks.

Editas Medicine is a biotechnology business based in the US. Editas Medicine stocks (EDIT.US) are listed on the NASDAQ and all prices are listed in US Dollars. Its last market close was $56.52 – a decrease of 14.98% over the previous week. Editas Medicine employs 235 staff and has a trailing 12-month revenue of around $24.5 million.

How to buy shares in Editas Medicine

  1. Compare share trading platforms. Use our comparison table to help you find a platform that fits you.
  2. Open your brokerage account. Complete an application with your details.
  3. Confirm your payment details. Fund your account.
  4. Research the stock. Find the stock by name or ticker symbol – EDIT – and research it before deciding if it's a good investment for you.
  5. Purchase now or later. Buy your desired number of shares with a market order or use a limit order to delay your purchase until the stock reaches a desired price.
  6. Check in on your investment. Optimize your portfolio by tracking your stock.

Editas Medicine stock price (NASDAQ:EDIT)

Use our graph to track the performance of EDIT stocks over time.

Editas Medicine shares at a glance

Information last updated 2022-01-17.
Latest market close$18.79
52-week range$20.90 - $74.55
50-day moving average $30.76
200-day moving average $41.20
Wall St. target price$49.71
PE ratio N/A
Dividend yield N/A (0%)
Earnings per share (TTM) $-3.23

Compare online stock trading platforms

Note: The dollar amounts in the table below are in Canadian dollars.

Name Product Finder Rating Stock Trading Fee Account Fee Available Asset Types Offer
FREE TRADES
Wealthsimple Trade
Finder Rating:
★★★★★
3.9 / 5
$0
$0
Stocks, ETFs
Get 2 free stocks when you deposit and trade $150.
Scotia iTRADE
Finder Rating:
★★★★★
3.8 / 5
$4.99 - $9.99
$0
Bonds, Options, Mutual Funds, ETFs, GICs, International Equities
Interactive Brokers
Finder Rating:
★★★★★
4.1 / 5
Min. $1.00, Max. 0.5%
$0
Stocks, Bonds, Options, ETFs, Currencies, Futures
OFFER
CIBC Investor's Edge
Finder Rating:
★★★★★
4 / 5
$4.95 - $6.95
$0 if conditions met, otherwise $100/year
Stocks, Bonds, Options, Mutual Funds, ETFs
Get up to $2,000 cash back. Conditions apply. Offer ends March 1, 2022.
Questrade
Finder Rating:
★★★★★
4.2 / 5
$4.95 - $9.95
$0
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs, International Equities, Precious Metals
Get $50 in free trades when you fund your account with a minimum of $1,000.
Qtrade Direct Investing
Finder Rating:
★★★★★
4.1 / 5
$6.95 - $8.75
$0 if conditions met, otherwise $25/quarter
Stocks, Bonds, Options, Mutual Funds, ETFs, GICs
Get a $50 bonus when you open a new RRSP, TFSA or RESP and start pre-authorized contributions of $200+/month. Valid until March 1, 2022.
loading

Compare up to 4 providers

Online stock trading

Is it a good time to buy Editas Medicine stock?

The technical analysis gauge below displays real-time ratings for the timeframes you select. This is not a recommendation, however. It represents a technical analysis based on the most popular technical indicators: Moving Averages, Oscillators and Pivots. Finder might not concur and takes no responsibility.

Editas Medicine price performance over time

Historical closes compared with the close of $18.79 from 2022-01-20

1 week (2022-01-13) -14.08%
1 month (2021-12-21) -36.99%
3 months (2021-10-21) -51.16%
6 months (2021-07-21) -57.38%
1 year (2021-01-21) -70.54%
2 years (2020-01-21) -37.22%
3 years (2019-01-18) 26.14
5 years (2017-01-20) 2.57%

Editas Medicine financials

Revenue TTM $24.5 million
Gross profit TTM $-67,264,000
Return on assets TTM -20.68%
Return on equity TTM -41.55%
Profit margin 0%
Book value $8.68
Market capitalisation $1.5 billion

TTM: trailing 12 months

Editas Medicine share dividends

We're not expecting Editas Medicine to pay a dividend over the next 12 months.

Editas Medicine share price volatility

Over the last 12 months, Editas Medicine's shares have ranged in value from as little as $20.9 up to $74.55. A popular way to gauge a stock's volatility is its "beta".

EDIT.US volatility(beta: 1.91)Avg. volatility(beta: 1.00)LowHigh

Beta is a measure of a share's volatility in relation to the market. The market (NASDAQ average) beta is 1, while Editas Medicine's is 1.9123. This would suggest that Editas Medicine's shares are more volatile than the average for this exchange and represent, relatively-speaking, a higher risk (but potentially also market-beating returns).

Editas Medicine overview

Editas Medicine, Inc. , a clinical stage genome editing company, focuses on developing transformative genomic medicines to treat a range of serious diseases. It develops a proprietary genome editing platform based on CRISPR technology to target genetically addressable diseases and therapeutic areas. The company develops EDIT-101, which is in Phase 1/2 clinical trial for Leber Congenital Amaurosis type 10, a genetic form of vision loss that leads to blindness in childhood. It also develops EDIT-102 for the treatment of Usher Syndrome 2A, which is a form of retinitis pigmentosa that also includes hearing loss; autosomal dominant retinitis pigmentosa 4, a progressive form of retinal degeneration; and EDIT-301 to treat sickle cell disease and beta-thalassemia. In addition, the company is developing gene-edited Natural Killer cell medicines to treat solid tumors; alpha-beta T cells for multiple cancers; and gamma delta T cell therapies to treat cancer, as well as has a early discovery program to develop a therapy to treat a neurological disease. It has a research collaboration with Juno Therapeutics, Inc.

Stocks similar to Editas Medicine

Frequently asked questions

Disclaimer: This information should not be interpreted as an endorsement of futures, stocks, ETFs, CFDs, options or any specific provider, service or offering. It should not be relied upon as investment advice or construed as providing recommendations of any kind. Futures, stocks, ETFs and options trading involves substantial risk of loss and therefore are not appropriate for all investors. Trading CFDs and forex on leverage comes with a higher risk of losing money rapidly. Past performance is not an indication of future results. Consider your own circumstances, and obtain your own advice, before making any trades.

More on investing

More guides on Finder

Go to site